DE69328186D1 - Zusammensetzung zur behandlung der parkinson-krankheit - Google Patents

Zusammensetzung zur behandlung der parkinson-krankheit

Info

Publication number
DE69328186D1
DE69328186D1 DE69328186T DE69328186T DE69328186D1 DE 69328186 D1 DE69328186 D1 DE 69328186D1 DE 69328186 T DE69328186 T DE 69328186T DE 69328186 T DE69328186 T DE 69328186T DE 69328186 D1 DE69328186 D1 DE 69328186D1
Authority
DE
Germany
Prior art keywords
disease
composition
antagonists
treating parkinson
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328186T
Other languages
English (en)
Other versions
DE69328186T2 (de
Inventor
Ram Kaminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69328186D1 publication Critical patent/DE69328186D1/de
Application granted granted Critical
Publication of DE69328186T2 publication Critical patent/DE69328186T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69328186T 1992-09-30 1993-09-27 Zusammensetzung zur behandlung der parkinson-krankheit Expired - Fee Related DE69328186T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/954,258 US5352688A (en) 1991-02-14 1992-09-30 Methods for the treatment of bradyphrenia in parkinson's disease
PCT/US1993/009191 WO1994007490A1 (en) 1992-09-30 1993-09-27 Method and composition for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
DE69328186D1 true DE69328186D1 (de) 2000-04-27
DE69328186T2 DE69328186T2 (de) 2000-12-21

Family

ID=25495171

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328186T Expired - Fee Related DE69328186T2 (de) 1992-09-30 1993-09-27 Zusammensetzung zur behandlung der parkinson-krankheit

Country Status (9)

Country Link
US (2) US5352688A (de)
EP (1) EP0665749B1 (de)
AT (1) ATE190840T1 (de)
AU (1) AU688739B2 (de)
CA (1) CA2145521A1 (de)
DE (1) DE69328186T2 (de)
DK (1) DK0665749T3 (de)
IL (1) IL107134A (de)
WO (1) WO1994007490A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
DE69532039T2 (de) * 1994-08-30 2004-07-08 Sankyo Co., Ltd. Isoxazole
US5837716A (en) * 1995-11-13 1998-11-17 Albany Medical College Analgesic heterocyclic compounds
EP1003554B1 (de) 1997-07-25 2004-11-03 ALTANA Pharma AG Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
HUP0002154A3 (en) * 2000-06-06 2002-06-28 Richter Gedeon Vegyeszet Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
EP2603215A4 (de) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Neue d3-dopamin-rezeptoragonisten zur behandlung von dyskinesien bei morbus parkinson
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
JP6607852B2 (ja) 2013-10-28 2019-11-20 ドレクセル ユニバーシティ 注意障害用および認知障害用ならびに神経変性障害に関連する認知症用の治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG39661A1 (en) * 1984-04-13 1986-08-29 Ivanova Antiulcer means
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease

Also Published As

Publication number Publication date
US5352688A (en) 1994-10-04
ATE190840T1 (de) 2000-04-15
EP0665749B1 (de) 2000-03-22
US5547969A (en) 1996-08-20
IL107134A0 (en) 1993-12-28
DE69328186T2 (de) 2000-12-21
CA2145521A1 (en) 1994-04-14
EP0665749A1 (de) 1995-08-09
WO1994007490A1 (en) 1994-04-14
AU688739B2 (en) 1998-03-19
EP0665749A4 (de) 1996-04-10
IL107134A (en) 1998-02-22
AU5292993A (en) 1994-04-26
DK0665749T3 (da) 2000-08-28

Similar Documents

Publication Publication Date Title
DE69328186D1 (de) Zusammensetzung zur behandlung der parkinson-krankheit
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
DE3852773T2 (de) Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.
HK1130422A1 (en) A new use of deferiprone
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ES8306483A1 (es) Procedimiento de preparacion de las dibezooxepinas sustituidas y de sus sales de adicion con un acido mineral u organico
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
BG103512A (en) Substituted pyramidine compounds and their application
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
HUT62474A (en) Process for producing veterinary composition with antiparasitic effect
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
KR890007737A (ko) 진토작용을 하는 약제
KR890001555A (ko) 요산 배설용 조성물
RU92016559A (ru) Производные диалкокси-пиридинилбензимидазола, фармацевтическая композиция, способ ингибирования или лечения, способ их получения, применение и промежуточные соединения

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee